» Articles » PMID: 28209537

MisoREST: Surgical Versus Expectant Management in Women with an Incomplete Evacuation of the Uterus After Misoprostol Treatment for Miscarriage: A Cohort Study

Abstract

Objective: To assess the effectiveness of curettage versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for first trimester miscarriage.

Study Design: We conducted a multicenter cohort study alongside a randomized clinical trial (RCT) between June 2012 until July 2014. 27 Dutch hospitals participated. Women with an incomplete evacuation after misoprostol treatment for first trimester miscarriage who declined to participate in the RCT, received treatment of their preference; curettage (n=65) or expectant management (n=132). A successful outcome was defined as an empty uterus on sonography at six weeks or uneventful clinical follow-up. We furthermore assessed complication rate and (re)intervention rate RESULTS: Of the 197 women who declined to participate in the RCT, 65 preferred curettage and 132 expectant management. A successful outcome was observed in 62/65 women (95%) in the surgical group versus 112/132 women (85%) in the expectant group (RR 1.1, 95% CI 1.03-1.2), with complication rates of 6.2% versus 2.3%, respectively (RR 2.7, 95% CI 0.6-12).

Conclusion: In women with an incomplete evacuation of the uterus after misoprostol treatment, expectant management is an effective and safe option. This finding could restrain the use of curettage in women that have used misoprostol in the treatment of first trimester miscarriage.

Citing Articles

Economic evaluation of a randomized controlled trial comparing mifepristone and misoprostol with misoprostol alone in the treatment of early pregnancy loss.

Hamel C, Snijders M, Coppus S, Vandenbussche F, Braat D, Adang E PLoS One. 2022; 17(2):e0262894.

PMID: 35139105 PMC: 8827447. DOI: 10.1371/journal.pone.0262894.


Diagnostic criteria for retained products of conception-A scoping review.

Hamel C, van Wessel S, Carnegy A, Coppus S, Snijders M, Clark J Acta Obstet Gynecol Scand. 2021; 100(12):2135-2143.

PMID: 34244998 PMC: 9291104. DOI: 10.1111/aogs.14229.


Mifepristone followed by misoprostol compared with placebo followed by misoprostol as medical treatment for early pregnancy loss (the Triple M trial): A double-blind placebo-controlled randomised trial.

Hamel C, Coppus S, van den Berg J, Hink E, van Seeters J, van Kesteren P EClinicalMedicine. 2021; 32:100716.

PMID: 33681738 PMC: 7910666. DOI: 10.1016/j.eclinm.2020.100716.


A prospective observational study of the follow-up of medical management of early pregnancy failure.

Kumari P, Preethi R, Abraham A, Rathore S, Benjamin S, Gowri M J Family Med Prim Care. 2019; 8(12):3998-4002.

PMID: 31879649 PMC: 6924238. DOI: 10.4103/jfmpc.jfmpc_585_19.


Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: study protocol for a randomized double blinded placebo-controlled comparison (Triple M Trial).

van den Berg J, Hamel C, Snijders M, Coppus S, Vandenbussche F BMC Pregnancy Childbirth. 2019; 19(1):443.

PMID: 31775677 PMC: 6880504. DOI: 10.1186/s12884-019-2497-y.